Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com

Susan Bobulsky, Chief Commercial Officer for Adaptive Biotechnologies Corp (), sold 3,000 shares of common stock for a total of $75,000 on August 10, 2026. The shares were sold at a price of $25.00 each. The timing coincides with the stock trading near its 52-week high of $26.16, following a remarkable 94% gain over the past year.

The transaction was executed under a Rule 10b5-1 trading plan, which Ms. Bobulsky adopted on December 16, 2025. Following this sale, Ms. Bobulsky directly holds 396,989 shares of Adaptive Biotechnologies common stock. The company, valued at $4.05 billion, currently appears overvalued according to InvestingPro analysis, placing it among stocks on the Most Overvalued list. For deeper insights into ADPT’s valuation and access to exclusive ProTips, visit the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Adaptive Biotechnologies Corporation reported its second-quarter results, which showed a mixed performance. The company posted an adjusted loss of $0.25 per share, missing the analyst consensus estimate of a $0.14 loss per share. However, revenue for the quarter reached $71.6 million, surpassing the $65.8 million analyst estimate and marking a 22% increase from the previous year. BTIG raised its price target for Adeptus Biotechnologies to $25 from $24, maintaining a Buy rating, citing strong growth in the company’s core minimal residual disease business with a 49% year-over-year revenue increase. The clonoSEQ MRD test franchise also showed significant volume growth of 43% year-over-year. Guggenheim also raised its price target on Adeptus Biotechnologies shares to $25 from $22, while maintaining a Buy rating. The firm highlighted the company’s performance on volumes and increased usage among existing clonoSEQ users as key factors. These developments indicate ongoing interest and confidence from analysts in the company’s growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.